Although the combination has already been approved by the FDA for patients with PD-L1 expression-positive NSCLC, the survival benefits of nivolumab in combination with ipilimumab in people with PD-L1 expression negative are clinically significant.[57]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.